C Gridelli

Summary

Country: Italy

Publications

  1. ncbi The c-Met inhibitors: a new class of drugs in the battle against advanced nonsmall-cell lung cancer
    Assunta Sgambato
    Department of Clinical and Experimental Medicine, Second University of Naples, Italy
    Curr Pharm Des 18:6155-68. 2012
  2. ncbi Safety, resource use, and quality of life in paramount: a phase III study of maintenance pemetrexed versus placebo after induction pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer
    Cesare Gridelli
    S Giuseppe Moscati Hospital, Avellino, Italy
    J Thorac Oncol 7:1713-21. 2012
  3. ncbi Pemetrexed therapy in elderly patients with good performance status: analysis of two phase III trials of patients with nonsquamous non-small-cell lung cancer
    Cesare Gridelli
    Division of Medical Oncology, S G Moscati Hospital, Avellino, Italy
    Clin Lung Cancer 13:340-6. 2012
  4. ncbi First-line erlotinib followed by second-line cisplatin-gemcitabine chemotherapy in advanced non-small-cell lung cancer: the TORCH randomized trial
    Cesare Gridelli
    S G Moscati Hospital, Avellino, Italy
    J Clin Oncol 30:3002-11. 2012
  5. ncbi The role of EGFR tyrosine kinase inhibitors in the first-line treatment of advanced non small cell lung cancer patients harboring EGFR mutation
    A Sgambato
    Department of Clinical and Experimental Medicine, Second University of Naples, Naples Italy
    Curr Med Chem 19:3337-52. 2012
  6. ncbi Maintenance treatment of advanced non-small-cell lung cancer: results of an international expert panel meeting of the Italian association of thoracic oncology
    Cesare Gridelli
    Medical Oncology, S G Moscati Hospital, Avellino, Italy
    Lung Cancer 76:269-79. 2012
  7. ncbi Targeting angiogenesis for treatment of NSCLC brain metastases
    C Schettino
    Division of Medical Oncology, S G Moscati Hospital, Avellino, Italy
    Curr Cancer Drug Targets 12:289-99. 2012
  8. ncbi Treatment decision-making for advanced non-small cell lung cancer and differences among European countries: 1st AIOT-ETOP meeting
    Cesare Gridelli
    Division of Medical Oncology, S G Moscati Hospital, Contrada Amoretta, Avellino, Italy
    Lung Cancer 74:544-8. 2011
  9. ncbi Medical treatment choices for patients affected by advanced NSCLC in routine clinical practice: results from the Italian observational "SUN" (Survey on the lUng cancer maNagement) study
    Cesare Gridelli
    Azienda Ospedaliera S Giuseppe Moscati, Avellino, Italy
    Lung Cancer 74:462-8. 2011
  10. ncbi Cisplatin plus gemcitabine or vinorelbine for elderly patients with advanced non small-cell lung cancer: the MILES-2P studies
    Cesare Gridelli
    Division of Medical Oncology, S G Moscati Hospital, Avellino, Italy
    J Clin Oncol 25:4663-9. 2007

Detail Information

Publications123 found, 100 shown here

  1. ncbi The c-Met inhibitors: a new class of drugs in the battle against advanced nonsmall-cell lung cancer
    Assunta Sgambato
    Department of Clinical and Experimental Medicine, Second University of Naples, Italy
    Curr Pharm Des 18:6155-68. 2012
    ..This review will explain the MET signaling pathway and biology in cancer and the recent clinical development and advances of MET/HGF targeting agents in the treatment of advanced NSCLC...
  2. ncbi Safety, resource use, and quality of life in paramount: a phase III study of maintenance pemetrexed versus placebo after induction pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer
    Cesare Gridelli
    S Giuseppe Moscati Hospital, Avellino, Italy
    J Thorac Oncol 7:1713-21. 2012
    ..In a phase III, randomized, double-blind study (PARAMOUNT), maintenance pemetrexed demonstrated significant benefit in advanced non-small-cell lung cancer (NSCLC). We present safety, resource use, and quality of life (QoL) results...
  3. ncbi Pemetrexed therapy in elderly patients with good performance status: analysis of two phase III trials of patients with nonsquamous non-small-cell lung cancer
    Cesare Gridelli
    Division of Medical Oncology, S G Moscati Hospital, Avellino, Italy
    Clin Lung Cancer 13:340-6. 2012
    ..The objective of these analyses was to evaluate the survival and safety of treatment with pemetrexed in elderly patients with nonsquamous non-small-cell lung cancer (NSCLC) and PS 0-1...
  4. ncbi First-line erlotinib followed by second-line cisplatin-gemcitabine chemotherapy in advanced non-small-cell lung cancer: the TORCH randomized trial
    Cesare Gridelli
    S G Moscati Hospital, Avellino, Italy
    J Clin Oncol 30:3002-11. 2012
    ..A randomized phase III trial was designed to test whether first-line erlotinib followed at progression by cisplatin-gemcitabine was not inferior in terms of survival to the standard inverse sequence...
  5. ncbi The role of EGFR tyrosine kinase inhibitors in the first-line treatment of advanced non small cell lung cancer patients harboring EGFR mutation
    A Sgambato
    Department of Clinical and Experimental Medicine, Second University of Naples, Naples Italy
    Curr Med Chem 19:3337-52. 2012
    ..This review will discuss the new evidences in the role of EGFR-TKIs in the first-line treatment of advanced NSCLC and their implication in the current clinical decision-making...
  6. ncbi Maintenance treatment of advanced non-small-cell lung cancer: results of an international expert panel meeting of the Italian association of thoracic oncology
    Cesare Gridelli
    Medical Oncology, S G Moscati Hospital, Avellino, Italy
    Lung Cancer 76:269-79. 2012
    ..Translational research is essential to identify predictive factors, and should be performed, whenever feasible, in order to achieve treatment optimization with proper patient selection...
  7. ncbi Targeting angiogenesis for treatment of NSCLC brain metastases
    C Schettino
    Division of Medical Oncology, S G Moscati Hospital, Avellino, Italy
    Curr Cancer Drug Targets 12:289-99. 2012
    ..This review will focus on the potential role of bevacizumab and other anti-angiogenetic agents in the treatment of brain metastases from NSCLC...
  8. ncbi Treatment decision-making for advanced non-small cell lung cancer and differences among European countries: 1st AIOT-ETOP meeting
    Cesare Gridelli
    Division of Medical Oncology, S G Moscati Hospital, Contrada Amoretta, Avellino, Italy
    Lung Cancer 74:544-8. 2011
    ....
  9. ncbi Medical treatment choices for patients affected by advanced NSCLC in routine clinical practice: results from the Italian observational "SUN" (Survey on the lUng cancer maNagement) study
    Cesare Gridelli
    Azienda Ospedaliera S Giuseppe Moscati, Avellino, Italy
    Lung Cancer 74:462-8. 2011
    ..3% of patients. These results showed a pattern of care for advanced NSCLC that reflects the current clinical practice in Italy at the study time with a high adherence to the International guidelines by the Italian Oncologists...
  10. ncbi Cisplatin plus gemcitabine or vinorelbine for elderly patients with advanced non small-cell lung cancer: the MILES-2P studies
    Cesare Gridelli
    Division of Medical Oncology, S G Moscati Hospital, Avellino, Italy
    J Clin Oncol 25:4663-9. 2007
    ..Two phase I/II trials were done to evaluate the feasibility of cisplatin combined with gemcitabine or vinorelbine in elderly patients with advanced non-small-cell lung cancer (NSCLC)...
  11. ncbi Erlotinib in non-small-cell lung cancer
    Cesare Gridelli
    S G Moscati Hospital, Division of Medical Oncology, Città Ospedaliera, Contrada Amoretta, 83100 Avellino, Italy
    Expert Opin Pharmacother 8:2579-92. 2007
    ..Further investigations are ongoing to contribute to our understanding of the role of erlotinib in NSCLC treatment...
  12. ncbi The role of bevacizumab in the treatment of non-small cell lung cancer: current indications and future developments
    Cesare Gridelli
    Division of Medical Oncology, S G Moscati Hospital, Contrada Amoretta, Avellino, Italy
    Oncologist 12:1183-93. 2007
    ....
  13. ncbi Clinical significance and treatment of skin rash from erlotinib in non-small cell lung cancer patients: results of an Experts Panel Meeting
    C Gridelli
    Division of Medical Oncology, SG Moscati Hospital, Contrada Amoretta, 83100 Avellino, Italy
    Crit Rev Oncol Hematol 66:155-62. 2008
    ....
  14. ncbi Second-line treatment of advanced non-small cell lung cancer
    Cesare Gridelli
    Medical Oncology, S G Moscati Hospital, Avellino, Italy
    J Thorac Oncol 3:430-40. 2008
    ..Further research is mandatory, to find better treatments, and to identify clinical and molecular predictive markers of efficacy, both for chemotherapy and for novel biologic agents...
  15. ncbi A randomized phase II study of pemetrexed or RAD001 as second-line treatment of advanced non-small-cell lung cancer in elderly patients: treatment rationale and protocol dynamics
    Cesare Gridelli
    Division of Medical Oncology, S G Moscati Hospital, Città Ospedaliera, Contrada Amoretta, Avellino, Italy
    Clin Lung Cancer 8:568-71. 2007
    ..Based on the statistical design, the investigators plan to enroll 92 elderly patients, 46 per arm...
  16. ncbi Targeted therapy developments in the treatment of non-small cell lung cancer: a promising but long and winding road
    Cesare Gridelli
    Division of Medical Oncology, S.G. Moscati Hospital, Avellino, Italy
    Curr Opin Oncol 20:145-7. 2008
  17. ncbi The potential role of mTOR inhibitors in non-small cell lung cancer
    Cesare Gridelli
    Division of Medical Oncology, S G Moscati Hospital, Contrada Amoretta, 83100 Avellino, Italy
    Oncologist 13:139-47. 2008
    ..Here, we review the basic structure of the pathway together with current results and future developments of mTOR inhibitors in the treatment of NSCLC patients...
  18. ncbi New insights in drug development for the non-small cell lung cancer therapy
    Cesare Gridelli
    Division of Medical Oncology, S G Moscati Hospital, Avellino, Italy
    Front Biosci 13:5108-19. 2008
    ..Aim of this review is to discuss about the new insights in targeted agents development for the treatment of NSCLC patients...
  19. ncbi Three cases of long-lasting tumor control with erlotinib after progression with gefitinib in advanced non-small cell lung cancer
    Cesare Gridelli
    Division of Medical Oncology, S G Moscati Hospital, Avellino, Italy
    J Thorac Oncol 2:758-61. 2007
    ..We report the cases of three patients with advanced non-small cell lung cancer responding to erlotinib after progression under gefitinib treatment...
  20. ncbi Erlotinib in non-small cell lung cancer treatment: current status and future development
    Cesare Gridelli
    Division of Medical Oncology, SG Moscati Hospital, Città Ospedaliera, Contrada Amoretta, Avellino, Italy
    Oncologist 12:840-9. 2007
    ....
  21. ncbi The use of bisphosphonates in elderly cancer patients
    Cesare Gridelli
    Division of Medical Oncology, SG Moscati Hospital, Contrada Amoretta, 83100 Avellino, Italy
    Oncologist 12:62-71. 2007
    ..Clinical trials of bisphosphonates in this patient population are currently under way, and their results are keenly awaited...
  22. ncbi Adjuvant chemotherapy in elderly patients with non-small-cell lung cancer
    Cesare Gridelli
    Division of Medical Oncology, S G Moscati Hospital, Contrada Amoretta, Avellino, Italy
    Cancer Control 14:57-62. 2007
    ..More than two thirds of patients who die of lung cancer in the United States are over 65 years of age. More than 50% of lung cancer patients are diagnosed over the age of 65 and about 30% over the age of 70...
  23. ncbi Targeted therapies and non-small-cell lung cancer: new developments
    Cesare Gridelli
    Division of Medical Oncology, S.G. Moscati Hospital, Avellino, Italy
    Curr Opin Oncol 19:75-7. 2007
  24. ncbi Sorafenib and sunitinib in the treatment of advanced non-small cell lung cancer
    Cesare Gridelli
    Division of Medical Oncology, S G Moscati Hospital, Contrada Amoretta, 83100 Avellino, Italy
    Oncologist 12:191-200. 2007
    ..Their mechanism of action, preclinical data, and phase II studies suggest efficacy in the treatment of advanced NSCLC...
  25. ncbi Role of colony stimulating factors (CSFs) in solid tumours: results of an expert panel
    Cesare Gridelli
    Division of Medical Oncology, S G Moscati Hospital, Contrada Amoretta, 83100 Avellino, Italy
    Crit Rev Oncol Hematol 63:53-64. 2007
    ..A special focus is dedicated to neutropenia and the use of CSFs in the treatment of the three "big killers" among the solid tumours: breast cancer, lung cancer and colorectal cancer...
  26. ncbi Single-agent pemetrexed or sequential pemetrexed/gemcitabine as front-line treatment of advanced non-small cell lung cancer in elderly patients or patients ineligible for platinum-based chemotherapy: a multicenter, randomized, phase II trial
    Cesare Gridelli
    Division of Medical Oncology, S G Moscati Hospital, Avellino, Italy
    J Thorac Oncol 2:221-9. 2007
    ....
  27. ncbi Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating Epidermal Growth Factor Receptor mutation: implications for clinical practice and open issues
    C Gridelli
    Division of Medical Oncology, SG Moscati Hospital, Avellino, Italy
    Lung Cancer 72:3-8. 2011
    ..Personalized medicine for patients with lung cancer is now a reality, and patients with EGFR mutation should be treated with first-line EGFR tyrosine kinase inhibitor...
  28. ncbi Lung cancer in the elderly
    Cesare Gridelli
    Division of Medical Oncology, S G Moscati Hospital, Avellino, Italy
    J Clin Oncol 25:1898-907. 2007
    ..Elderly patients often have comorbidities and other characteristics that make the selection of treatment daunting...
  29. ncbi Factorial phase III randomised trial of rofecoxib and prolonged constant infusion of gemcitabine in advanced non-small-cell lung cancer: the GEmcitabine-COxib in NSCLC (GECO) study
    Cesare Gridelli
    Medical Oncology, S Giuseppe Moscati Hospital, Avellino, Italy
    Lancet Oncol 8:500-12. 2007
    ..We aimed to assess whether the addition of rofecoxib or PCI gemcitabine could improve overall survival compared with first-line treatment with cisplatin plus gemcitabine given by standard infusion...
  30. ncbi Informal caregiving burden in advanced non-small cell lung cancer: the HABIT study
    Cesare Gridelli
    Division of Medical Oncology, S G Moscati Hospital, Avellino, Italy
    J Thorac Oncol 2:475-80. 2007
    ..This study's aim was to assess economic data regarding the home assistance burden for advanced non-small cell lung cancer (NSCLC) patients in Italy...
  31. ncbi An international, multicenter, randomized phase III study of first-line erlotinib followed by second-line cisplatin/gemcitabine versus first-line cisplatin/gemcitabine followed by second-line erlotinib in advanced non-small-cell lung cancer: treatment rat
    Cesare Gridelli
    Division of Medical Oncology, SG Moscati Hospital, Avellino, Italy
    Clin Lung Cancer 9:235-8. 2008
    ..The study design is based on a noninferiority survival comparison with about 900 patients expected to be recruited. An early analysis of activity will be performed in the experimental arm (first-line erlotinib followed by chemotherapy)...
  32. ncbi The MILES-2G phase 2 study of single-agent gemcitabine with prolonged constant infusion in advanced non-small cell lung cancer elderly patients
    Cesare Gridelli
    Medical Oncology, S Giuseppe Moscati Hospital, Avellino, Italy
    Lung Cancer 61:67-72. 2008
    ..Aim of this study is to describe activity and toxicity of single-agent gemcitabine given as prolonged infusion in the treatment of elderly patients with advanced NSCLC...
  33. ncbi The role of maintenance treatment in advanced non-small-cell lung cancer: reality or early second line?
    Cesare Gridelli
    Division of Medical Oncology, San Giuseppe Moscati Hospital, Avellino, Italy
    Clin Lung Cancer 11:374-82. 2010
    ..Here, we attempt to define the different approaches that fall under the rubric of maintenance strategy, and discuss the results available to date...
  34. ncbi Unanswered questions: monoclonal antibodies in the treatment of advanced non-small-cell lung cancer
    Cesare Gridelli
    Division of Medical Oncology, S G Moscati Hospital, Avellino, Italy
    Oncology (Williston Park) 24:1216-23. 2010
    ....
  35. ncbi Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating epidermal growth factor receptor mutation: Review of the evidence
    C Gridelli
    Division of Medical Oncology, S G Moscati Hospital, Avellino, Italy
    Lung Cancer 71:249-57. 2011
    ..Gefitinib currently represents the best first-line treatment option for this molecularly selected subgroup of patients...
  36. ncbi Pemetrexed in advanced non-small cell lung cancer
    Cesare Gridelli
    S G Moscati Hospital, Division of Medical Oncology, Contrada Amoretta, 83100 Avellino, Italy
    Expert Opin Drug Saf 10:311-7. 2011
    ..Furthermore, cisplatin plus pemetrexed has a more favorable safety profile as compared with those of pre-existing cisplatin-based regimens...
  37. ncbi Treatment, rationale, and study design of TALISMAN study: a randomized phase II open-label study of second-line erlotinib versus intermittent erlotinib dosing with docetaxel in the treatment of former-smoker men affected by recurrent squamous non-small-ce
    Cesare Gridelli
    Division of Medical Oncology, San Giuseppe Moscati Hospital, Avellino, Italy
    Clin Lung Cancer 12:70-3. 2011
    ..In addition, translational research evaluating EGFR and KRAS mutational status will be investigated for both arms...
  38. ncbi Vaccines for the treatment of non-small cell lung cancer: a renewed anticancer strategy
    Cesare Gridelli
    Division of Medical Oncology, S G Moscati Hospital, Avellino, Italy
    Oncologist 14:909-20. 2009
    ..This paper reviews the main clinical trials involving several different cancer vaccines employed in the treatment of early and advanced stage NSCLC, focusing on those in advanced stages of development...
  39. ncbi Non-small cell lung cancer therapy in the elderly
    Cesare Gridelli
    Division of Medical Oncology, S G Moscati Hospital, 83100 Avellino, Italy
    Clin Adv Hematol Oncol 9:375-83. 2011
    ..Future trials, specifically in the elderly population, should include these kinds of evaluations. The most recent therapies for the treatment of elderly patients with NSCLC will be discussed here...
  40. ncbi Randomized phase IIIb trial evaluating the continuation of bevacizumab beyond disease progression in patients with advanced non-squamous non-small-cell lung cancer after first-line treatment with bevacizumab plus platinum-based chemotherapy: treatment rat
    Cesare Gridelli
    Division of Medical Oncology, SG Moscati Hospital, Avellino, Italy
    Clin Lung Cancer 12:407-11. 2011
    ....
  41. ncbi Phase I-II trial of gemcitabine-based first-line chemotherapies for small cell lung cancer in elderly patients with performance status 0-2: the G-STEP trial
    Cesare Gridelli
    Medical Oncology, S Giuseppe Moscati Hospital, Avellino, Italy
    J Thorac Oncol 7:233-42. 2012
    ..Treatment of elderly patients with small cell lung cancer (SCLC) is based on scanty evidence...
  42. ncbi Erlotinib in the treatment of non-small cell lung cancer: current status and future developments
    Cesare Gridelli
    Division of Medical Oncology, S G Moscati Hospital, Contrada Amoretta, Avellino, Italy
    Anticancer Res 30:1301-10. 2010
    ..The present review discusses the role of erlotinib in the treatment of NSCLC...
  43. ncbi The potential role of insulin-like growth factor receptor inhibitors in the treatment of advanced non-small cell lung cancer
    Cesare Gridelli
    SG Moscati Hospital, Division of Medical Oncology, Avellino, Italy
    Expert Opin Investig Drugs 19:631-9. 2010
    ..NSCLC accounts for > 80% of all lung cancers. The treatment of advanced fit NSCLC patients seems to have reached a plateau. Considerable efforts have been initiated to identify new biological agents...
  44. ncbi New avenues for second-line treatment of metastatic non-small-cell lung cancer
    Cesare Gridelli
    Division of Medical Oncology, S G Moscati Hospital, Contrada Amoretta, Avellino, Italy
    Expert Rev Anticancer Ther 9:115-24. 2009
    ..Phase III trials with these agents are ongoing...
  45. ncbi Potential treatment options after first-line chemotherapy for advanced NSCLC: maintenance treatment or early second-line?
    Cesare Gridelli
    Division of Medical Oncology, SG Moscati Hospital, Contrada Amoretta, Avellino, Italy
    Oncologist 14:137-47. 2009
    ..Further studies are warranted to establish the role of maintenance chemotherapy in patients with advanced NSCLC...
  46. ncbi Cetuximab and gemcitabine in elderly or adult PS2 patients with advanced non-small-cell lung cancer: The cetuximab in advanced lung cancer (CALC1-E and CALC1-PS2) randomized phase II trials
    Cesare Gridelli
    Oncologia Medica, Az Sanitaria S Giuseppe Moscati, Avellino, Contrada Amoretta 83100, Italy
    Lung Cancer 67:86-92. 2010
    ..Two parallel randomized phase 2 trials were performed to choose the optimal way of combining cetuximab with gemcitabine in the first-line treatment of elderly (CALC1-E) and adult PS2 (CALC1-PS2) patients with advanced NSCLC...
  47. ncbi Vascular disrupting agents: a novel mechanism of action in the battle against non-small cell lung cancer
    Cesare Gridelli
    Division of Medical Oncology, SG Moscati Hospital, Contrada Amoretta, Città Ospedaliera, 83100 Avellino, Italy
    Oncologist 14:612-20. 2009
    ....
  48. ncbi Cetuximab and other anti-epidermal growth factor receptor monoclonal antibodies in the treatment of non-small cell lung cancer
    Cesare Gridelli
    Division of Medical Oncology, SG Moscati Hospital, Contrada Amoretta, Città Ospedaliera, 83100 Avellino, Italy
    Oncologist 14:601-11. 2009
    ..Other anti-EGFR monoclonal antibodies, such as panitumumab, matuzumab, nimotuzumab, and ch806, are in different stages of development for the treatment of advanced NSCLC...
  49. ncbi Treatment of advanced non-small-cell lung cancer in the elderly
    Cesare Gridelli
    Division of Medical Oncology, S G Moscati Hospital, Contrada Amoretta 83100, Avellino, Italy
    Lung Cancer 66:282-6. 2009
    ..Further specifically designed phase III randomized trials are needed to optimize medical treatment of NSCLC in elderly patients...
  50. ncbi Casopitant improves the quality of life in patients receiving highly emetogenic chemotherapy
    Cesare Gridelli
    Division of Medical Oncology, S G Moscati Hospital, Contrada Amoretta, 83100 Avellino, Italy
    Support Care Cancer 18:1437-44. 2010
    ..The objective of this study was to evaluate the impact of the addition of casopitant to dual-combination therapy of dexamethasone and ondansetron on quality of life in patients receiving highly emetogenic chemotherapy (HEC)...
  51. ncbi Recent issues in first-line treatment of advanced non-small-cell lung cancer: Results of an International Expert Panel Meeting of the Italian Association of Thoracic Oncology
    Cesare Gridelli
    Medical Oncology, S G Moscati Hospital, Avellino, Italy
    Lung Cancer 68:319-31. 2010
    ..Although the number of treatment options for patients with advanced NSCLC has increased recently, their results remain modest and further research is mandatory...
  52. ncbi The role of pemetrexed as maintenance treatment in advanced NSCLC: a Phase III randomized trial
    Cesare Gridelli
    S G Moscati Hospital, Division of Medical Oncology, Contrada Amoretta 83100, Avellino, Italy
    Expert Opin Pharmacother 11:321-4. 2010
    ....
  53. ncbi The role of antiangiogenetic agents in the treatment of breast cancer
    M A Bareschino
    Division of Medical Oncology, Department of Clinical and Experimental Medicine and Surgery F Magrassi and A Lanzara, Second University of Naples, School of Medicine, Via S Pansini 5, 80131 Naples, Italy
    Curr Med Chem 18:5022-32. 2011
    ..This review will focus on bevacizumab and on the developements of the main antiangiogenic agents in the treatment of breast cancer...
  54. ncbi Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial
    Cesare Gridelli
    J Natl Cancer Inst 95:362-72. 2003
    ..We compared the effectiveness and toxicity of the combination of vinorelbine plus gemcitabine with those of each drug given alone in an open-label, randomized phase III trial in elderly patients with advanced NSCLC...
  55. ncbi Treatment of advanced non-small-cell lung cancer in the elderly: results of an international expert panel
    Cesare Gridelli
    Division of Medical Oncology, S G Moscati Hospital, Via Circumvallazione 68, 83100 Avellino, Italy
    J Clin Oncol 23:3125-37. 2005
    ..Best supportive care remains important, in addition to chemotherapy or as the exclusive option for patients who are unsuitable for more aggressive treatment...
  56. ncbi Treatment of locally advanced non-small cell lung cancer in the elderly
    C Gridelli
    Division of Medical Oncology, S G Moscati Hospital, Avellino, Italy
    Curr Opin Oncol 17:130-4. 2005
    ..The present review aims at focusing the currently available evidences on the treatment of elderly patients affected by locally advanced NSCLC and at giving future perspectives on this topic...
  57. ncbi A randomised clinical trial of two docetaxel regimens (weekly vs 3 week) in the second-line treatment of non-small-cell lung cancer. The DISTAL 01 study
    C Gridelli
    Oncologia Medica, Azienda Ospedaliera S Giuseppe Moscati, Avellino, Italy
    Br J Cancer 91:1996-2004. 2004
    ..The weekly schedule could be preferred for patients candidate to receive docetaxel as second-line treatment for advanced NSCLC, because of some QoL advantages, lower toxicity and no evidence of strikingly different effect on survival...
  58. ncbi Oral vinorelbine given as monotherapy to advanced, elderly NSCLC patients: a multicentre phase II trial
    C Gridelli
    Unita Operativa di Oncologia Medica, Azienda Ospedaliera S G Moscati, Via Circumvallazione 68, Avellino 83100, Italy
    Eur J Cancer 40:2424-31. 2004
    ..v. administration. Oral vinorelbine appears to be a reasonable alternative to i.v. vinorelbine, both in terms of activity and tolerability, in advanced, elderly NSCLC patients...
  59. ncbi Gefitinib in elderly and unfit patients affected by advanced non-small-cell lung cancer
    C Gridelli
    Division of Medical Oncology, SG Moscati Hospital Via Circumvallazione, Avellino 83100, Italy
    Br J Cancer 89:1827-9. 2003
    ..Special approaches are needed for these patient populations. Gefitinib (Iressa) was used in 59 elderly and/or unfit NSCLC pretreated patients participating in a compassionate use programme showing some activity and good tolerability...
  60. ncbi Potential role of molecularly targeted therapy in the management of advanced nonsmall cell lung carcinoma in the elderly
    Cesare Gridelli
    Division of Medical Oncology, San Giuseppe Moscati Hospital, Avellino, Italy
    Cancer 101:1733-44. 2004
    ..For such elderly patients, alternatives to conventional chemotherapy, such as novel molecularly targeted therapy regimens, are of interest...
  61. ncbi Gefitinib as salvage therapy in pretreated patients with advanced non-small cell lung cancer. Data from a compassionate use program
    Cesare Gridelli
    UO Oncologia Medica, Azienda Ospedaliera S G Moscati, Avellino, Italy
    Anticancer Res 24:1873-7. 2004
    ..To evaluate the tolerabiliy and activity of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with pretreated advanced non-small cell lung cancer (NSCLC)...
  62. ncbi Same old story? Do we need to modify our supportive care treatment of elderly cancer patients? Focus on antiemetics
    Cesare Gridelli
    Division of Medical Oncology, S G Moscati Hospital, Avellino, Italy
    Drugs Aging 21:825-32. 2004
    ....
  63. ncbi Factors influencing the choice of 5-HT3-receptor antagonist antiemetics: focus on elderly cancer patients
    Cesare Gridelli
    Division of Medical Oncology, S G Moscati Hospital, Via Circumvallazione, 83100 Avellino, Italy
    Support Care Cancer 12:487-96. 2004
    ..g., the risk of drug interactions and potential adverse effects), and simplicity of the dosing regimen. The focus of this review is on some of the pertinent issues of 5-HT(3) antagonists relating to elderly cancer patients...
  64. ncbi Treatment of non-small-cell lung cancer: state of the art and development of new biologic agents
    Cesare Gridelli
    Division of Medical Oncology, S G Moscati Hospital, Via Circumvallazione, Avellino, 83100, Italy
    Oncogene 22:6629-38. 2003
    ..However, important lessons can be learned from this first generation of clinical trials that should be considered the first step of clinical research in this field...
  65. ncbi 5-HT3-receptor antagonists in the control of delayed-onset emesis
    Cesare Gridelli
    Division of Medical Oncology, S G Moscati Hospital, Via Circumvallazione, 83100 Avellino, Italy
    Anticancer Res 23:2773-82. 2003
    ..As a result, antiemetic guidelines recommend the addition of a 5-HT3-receptor antagonist for the treatment of delayed emesis, particularly for high-risk patients...
  66. ncbi Gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small-cell lung cancer: a phase III trial of the Italian GEMVIN Investigators and the National Cancer Institute of Canada Clinical Trials
    Cesare Gridelli
    Clinical Trials Unit, National Cancer Institute, Via M Semmola, 80131 Naples, Italy
    J Clin Oncol 21:3025-34. 2003
    ..This trial aimed to assess whether a combination of gemcitabine and vinorelbine had benefits in terms of QoL, without influencing negatively on survival, compared with cisplatin-containing regimens...
  67. ncbi Chemotherapy for elderly patients with non-small cell lung cancer: a review of the evidence
    Cesare Gridelli
    Division of Medical Oncology, S G Moscati Hospital, Via Circumvallazione 68, 83100 Avellino, Italy
    Chest 128:947-57. 2005
    ..The potential impact of new targeted therapies-alone or in combination with chemotherapy-is being investigated...
  68. ncbi The potential role of histone deacetylase inhibitors in the treatment of non-small-cell lung cancer
    Cesare Gridelli
    Division of Medical Oncology, S G Moscati Hospital, Contrada Amoretta, 83100 Avellino, Italy
    Crit Rev Oncol Hematol 68:29-36. 2008
    ..Here, we discuss about the potential role of HDAC inhibitors focusing on their activity, tolerability, efficacy and future development, in the treatment of NSCLC...
  69. ncbi Chemotherapy of advanced NSCLC in special patient population
    C Gridelli
    Division of Medical Oncology, S G Moscati Hospital, Avellino, Italy
    Ann Oncol 17:v72-8. 2006
    ..High priority should be given to the evaluation of tolerability and efficacy of platinum-based combinations and role of new targeted therapies...
  70. ncbi New antiangiogenetic agents and non-small cell lung cancer
    C Gridelli
    Division of Medical Oncology, S G Moscati Hospital, Contrada Amoretta, Avellino, Italy
    Crit Rev Oncol Hematol 60:76-86. 2006
    ..Data on antitumor activity of this combination have to be considered very promising. Clinical trials of multiple targeted therapy may represent the second generation studies in the treatment of NSCLC...
  71. ncbi Treatment of stage I-III non-small-cell lung cancer in the elderly
    Cesare Gridelli
    Division of Medical Oncology, SG Moscati Hospital, Avellino, Italy
    Oncology (Williston Park) 20:373-80; discussion 385-6, 388, 393 passim. 2006
    ..Only specifically designed prospective studies will elucidate the real role and feasibility of this combined approach in the treatment of unselected elderly patients...
  72. ncbi Management of unfit older patients with advanced NSCLC
    Cesare Gridelli
    Division of Medical Oncology, S G Moscati Hospital, Contrada Amoretta 83100, Avellino, Italy
    Cancer Treat Rev 35:517-21. 2009
    ..However, specific prospective investigation is absolutely warranted for this special population...
  73. ncbi A randomized phase II study of sorafenib/gemcitabine or sorafenib/erlotinib for advanced non-small-cell lung cancer in elderly patients or patients with a performance status of 2: treatment rationale and protocol dynamics
    Cesare Gridelli
    Division of Medical Oncology, S G Moscati Hospital, Avellino, Italy
    Clin Lung Cancer 8:396-8. 2007
    ..The study will enroll 100 patients: 58 patients aged >or= 70 years with a PS of 0-2 and 42 patients aged < 70 years with a PS of 2. The analysis will be conducted differently for the 2 groups of patients...
  74. ncbi Treatment of advanced non-small-cell lung cancer patients with ECOG performance status 2: results of an European Experts Panel
    C Gridelli
    Division of Medical Oncology, SG Moscati Hospital, Avellino, Italy
    Ann Oncol 15:419-26. 2004
    ..Patients strongly need symptomatic improvement: end points such as symptom relief, clinical benefit and quality of life should have a central position in trials dedicated to PS2 NSCLC patients...
  75. ncbi Italian clinical research in non-small-cell lung cancer
    C Gridelli
    Division of Medical Oncology, S.G. Moscati Hospital, Avellino, Italy
    Ann Oncol 16:iv110-115. 2005
    ..Today, large controlled clinical trials are ongoing. In this paper we analyse and discuss the main trials performed by Italian groups in the fields of NSCLC...
  76. ncbi Pemetrexed in the treatment of advanced non-squamous lung cancer
    Antonio Rossi
    Division of Medical Oncology, S G Moscati Hospital, Contrada Amoretta, 83100 Avellino, Italy
    Lung Cancer 66:141-9. 2009
    ..This review shows the latest and indicates the future developments of pemetrexed in the treatment of advanced NSCLC patients...
  77. ncbi Individual patient data meta-analysis of docetaxel administered once every 3 weeks compared with once every week second-line treatment of advanced non-small-cell lung cancer
    Massimo Di Maio
    Clinical Trials Unit, National Cancer Institute, Naples, Italy
    J Clin Oncol 25:1377-82. 2007
    ....
  78. ncbi Recent developments of targeted therapies in the treatment of non-small cell lung cancer
    Antonio Rossi
    Division of Medical Oncology, S G Moscati Hospital, Avellino, Italy
    Curr Drug Discov Technol 6:91-102. 2009
    ..This review shows the latest and the future developments of erlotinib, bevacizumab and ZD6474 in the treatment of advanced NSCLC patients...
  79. ncbi Vascular endothelial growth factor receptor as target for advanced non-small cell lung cancer therapy
    Antonio Rossi
    Division of Medical Oncology, S G Moscati Hospital, Contrada Amoretta 8, Avellino, Italy
    Curr Drug Targets 11:865-8784. 2010
    ..Here we review the current results and give an overview of some of the future developments of the main anti-VEGFR drugs in the treatment of NSCLC patients...
  80. ncbi Pretreatment quality of life and functional status assessment significantly predict survival of elderly patients with advanced non-small-cell lung cancer receiving chemotherapy: a prognostic analysis of the multicenter Italian lung cancer in the elderly s
    Paolo Maione
    S Giuseppe Moscati Hospital, Avellino, Italy
    J Clin Oncol 23:6865-72. 2005
    ..Using these scores in clinical practice might improve prognostic prediction for treatment planning...
  81. ncbi Chemotherapy of advanced non-small cell lung cancer in elderly patients
    A Rossi
    Division of Medical Oncology, S G Moscati Hospital, Avellino, Italy
    Ann Oncol 17:ii58-60. 2006
    ..High priority should be also given to the evaluation of the role of new targeted therapies. Moreover, a comprehensive geriatric assessment for individualized treatment choice in NSCLC elderly patients is mandatory...
  82. ncbi [Medical therapy of elderly patients with advanced non-small cell lung carcinoma: significance and possibilities]
    Cesare Gridelli
    , Azienda Ospedaliera San G Moscati, Avellino
    Suppl Tumori 3:S36-7. 2004
  83. ncbi Meeting the chemotherapy needs of elderly and poor performance status patients with NSCLC
    Cesare Gridelli
    Division of Medical Oncology, SG Moscati Hospital, Via Circumvallazione, Avellino 83100, Italy
    Lung Cancer 38:37-41. 2002
    ..The combination of gemcitabine and docetaxel, both administered weekly, is well tolerated by elderly and/or poor PS patients, is active (median survival 7 months, 1-year survival 29%) and merits further study...
  84. ncbi Does chemotherapy have a role as palliative therapy for unfit or elderly patients with non-small-cell lung cancer?
    Cesare Gridelli
    Division of Medical Oncology, SG Moscati Hospital, Via Circumvallazione, 83100 Avellino, Italy
    Lung Cancer 38:S45-50. 2002
    ..Results showed no benefit in response rate, time to progression, survival, and quality of life for the combination. Single-agent chemotherapy remains the standard treatment approach for elderly NSCLC patients with advanced disease...
  85. ncbi The role of targeted therapy in non-small cell lung cancer
    Paolo Maione
    , S.G. Moscati Hospital, Via Circumvallazione 68, 83100 Avellino, Italy
    Crit Rev Oncol Hematol 51:29-44. 2004
    ..Moreover, important lessons can be learned from this first generation of clinical trials...
  86. ncbi Chemotherapy-induced neutropenia and treatment efficacy in advanced non-small-cell lung cancer: a pooled analysis of three randomised trials
    Massimo Di Maio
    National Cancer Institute, Naples, Italy
    Lancet Oncol 6:669-77. 2005
    ..Prospective trials are needed to assess whether drug dosing guided by the occurrence of toxic effects could improve efficacy of standard regimens...
  87. ncbi Chemotherapy of non-small cell lung cancer in elderly patients
    C Gridelli
    Division of Medical Oncology, S G Moscati Hospital, Avellino, Italy
    Curr Med Chem 9:1487-95. 2002
    ..However, practicing a multidimensional geriatric awsessment for individualized treatment choice in NSCLC elderly patients is mandatory...
  88. ncbi Cetuximab in advanced non-small cell lung cancer
    Antonio Rossi
    Division of Medical Oncology, SG Moscati Hospital, Contrada Amoretta, Città Ospedaliera, Avellino, Italy
    Crit Rev Oncol Hematol 59:139-49. 2006
    ..In the present paper we discuss about the activity, tolerability and efficacy of cetuximab, the EGFR monoclonal blocking antibody with the largest amount of clinical data being available on the treatment of advanced NSCLC...
  89. ncbi The emerging role of histology in the choice of first-line treatment of advanced non-small cell lung cancer: implication in the clinical decision-making
    Antonio Rossi
    Division of Medical Oncology, S G Moscati Hospital, Contrada Amoretta, 8, 83100 Avellino, Italy
    Curr Med Chem 17:1030-8. 2010
    ..This review will discuss these new evidences in the first-line treatment of advanced NSCLC and their implication in the current clinical decision-making...
  90. ncbi Vinorelbine in the treatment of non-small cell lung cancer
    Cesare Gridelli
    Divisione di Oncologia Medica, Azienda Ospedaliera S G Moscati, Avellino, Italy
    Curr Med Chem 9:879-91. 2002
    ..in combined chemo-radiotherapy., in advanced disease and in the particular setting of the elderly. The oral use of vinorelbine will be among the future developments of this drug...
  91. ncbi The role of cetuximab and other epidermal growth factor receptor monoclonal antibodies in the treatment of advanced non-small cell lung cancer
    Antonio Rossi
    Division of Medical Oncology, S G Moscati Hospital, Contrada Amoretta, Città Ospedaliera, 83100 Avellino Italy
    Rev Recent Clin Trials 3:217-27. 2008
    ..This article will focus on cetuximab and other monoclonal antibodies and their applications in the treatment of advanced NSCLC...
  92. ncbi Trying to compose the puzzle with all the pieces: epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer
    Massimo Di Maio
    Clinical Trials Unit, National Cancer Institute of Naples, Naples, Italy
    J Cell Physiol 205:355-63. 2005
    ....
  93. ncbi Safety profile of gefitinib in advanced non-small cell lung cancer elderly patients with chronic renal failure: two clinical cases
    Antonio Rossi
    Unita Operativa di Oncologia Medica, Azienda Ospedaliera S.G. Moscati, Via Circumvallazione 68, 83100 Avellino, Italy
    Lung Cancer 47:421-3. 2005
    ..Gefitinib should be further evaluated as front-line treatment in a larger sample of such patients, in order to establish a therapeutic option for a sort of patients unsuitable for any chemotherapy...
  94. ncbi An expanded access program of erlotinib (Tarceva) in patients with advanced non-small cell lung cancer (NSCLC): data report from Italy
    Marcello Tiseo
    Oncologia Medica, Azienda Ospedaliero Universitaria, Parma, Italy
    Lung Cancer 64:199-206. 2009
    ..TRUST is a phase IV trial initiated to provide erlotinib access to patients with advanced NSCLC. We report the interim analysis for patients enrolled in the TRUST trial in Italy...
  95. ncbi Activity and toxicity of gemcitabine and gemcitabine + vinorelbine in advanced non-small-cell lung cancer elderly patients: Phase II data from the Multicenter Italian Lung Cancer in the Elderly Study (MILES) randomized trial
    C Gridelli
    Divisione di Oncologioca Medica B, Istituto Nazionale per lo Studio e la Cura dei Tumori, Via M Semmola, 80131 Naples, Italy
    Lung Cancer 31:277-84. 2001
    ....
  96. ncbi The ELVIS trial: a phase III study of single-agent vinorelbine as first-line treatment in elderly patients with advanced non-small cell lung cancer. Elderly Lung Cancer Vinorelbine Italian Study
    C Gridelli
    National Cancer Institute, Division of Medical Oncology B, Naples, Italy
    Oncologist 6:4-7. 2001
    ....
  97. ncbi Combining targeted therapies and drugs with multiple targets in the treatment of NSCLC
    Paolo Maione
    Division of Medical Oncology, S G Moscati Hospital, Contrada Amoretta, 83100 Avellino, Italy
    Oncologist 11:274-84. 2006
    ..Whether the multitargeted approach is best performed using combinations of selective agents or agents that intrinsically target various targets is a matter of debate...
  98. ncbi CD40 activation as potential tool in malignant neoplasms
    Alessandro Ottaiano
    Division of Medical Oncology B, National Cancer Institute G Pascale, Naples, Italy
    Tumori 88:361-6. 2002
    ..The general aim of this review is to focus the attention of clinical oncologists on the involvement of CD40 in tumors and the rationale of CD40-activation-based therapies in new, biologically oriented antitumor protocols...
  99. ncbi Advances in chemotherapy in advanced non-small-cell lung cancer
    Paolo Maione
    S G Moscati Hospital, Contrada Amoretta, Avellino, Italy
    Expert Opin Pharmacother 11:2997-3007. 2010
    ..Non-small-cell lung cancer (NSCLC) accounts for about 85% of all lung cancers diagnosis, and the majority of people diagnosed with NSCLC have advanced disease...
  100. ncbi Chemotherapy of breast cancer in the elderly
    A Rossi
    U.O. Oncologia Medica, Azienda Ospedaliera S.G. Moscati, Avellino, Italy
    Curr Med Chem 12:297-310. 2005
    ..The authors review the literature regarding age-specific chemotherapeutic issues in the management of breast cancer elderly patients...
  101. ncbi Surgical management of non-small cell lung cancer with mediastinal lymphadenopathy
    G Rocco
    Department of Thoracic Surgery and Oncology, National Cancer Institute, Pascale Foundation, Naples, Italy
    Clin Oncol (R Coll Radiol) 22:325-33. 2010
    ....